Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema

Hereditary angioedema (HAE) is rare disease characterized by recurrent, unpredictable, and debilitating attacks of subcutaneous/submucosal tissue swelling.1,2 The reported median age of onset of HAE due to C1 inhibitor deficiency/dysfunction (type 1/2; C1-INH-HAE) is 11-12 years.1,3 Treatment options for pediatric patients are limited, owing to low childhood diagnosis rates and low representation in investigative clinical trials.4 We present a multicenter, open-label, single-arm, phase 3 study (NCT01386658) investigating the use of icatibant, a bradykinin B2 receptor antagonist, to treat HAE attacks in pediatric patients with a confirmed diagnosis of C1-INH-HAE.5 In Part 1, patients (aged 2 to